|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape Analysis for US Patent 8,815,884
US 8,815,884 covers an oral pharmaceutical composition with a defined dose band for “the compound” (or a salt of the compound) and uses that composition to treat anemia associated with renal disease in humans. The patent is structurally narrow in formulation scope (dose range plus oral administration and generic excipients), but broad in therapeutic use within the anemia-renal disease indication and in the dose band framed as “1-700 mg.”
What does US 8,815,884 claim coverage actually cover?
Claim structure
The independent claim set is split into (1) composition for oral administration and (2) methods of treatment for anemia associated with renal disease in humans. Dependent claims tighten dose amounts and administration schedule.
Composition claims
- Claim 1: Oral pharmaceutical composition comprising 1–700 mg of the compound or a salt thereof plus one or more pharmaceutically acceptable carriers/diluents/excipients.
- Claim 2: Oral pharmaceutical composition comprising 1–700 mg of the compound plus pharmaceutically acceptable carriers/diluents/excipients.
- Claim 3: Composition of claim 2 with 5–100 mg of the compound.
Method claims
- Claim 4: Method of treating anemia associated with renal disease in a human by administering a composition according to claim 1.
- Claim 5: Method of treating anemia associated with renal disease by administering composition according to claim 2.
- Claim 6: Method of treating anemia associated with renal disease by administering composition according to claim 3.
- Claims 7–9: Each respective method claim specifies the composition is administered as a daily dose.
Practical scope read-through
The claims do not specify:
- dosage form type (tablet, capsule, solution, etc.),
- release profile (immediate vs sustained),
- specific excipients,
- patient subpopulation (CKD stage, dialysis status),
- frequency beyond “daily dose,”
- compound identity, mechanism, or chemical class (not provided in the claim text you supplied).
That omission matters for freedom-to-operate (FTO): infringement can be driven primarily by dose amount, oral route, and the anemia-renal disease therapeutic context, assuming the accused product uses the same compound or a salt that falls within “the compound.”
How broad is the dose and where are the claim cliffs?
Dose bands
The patent sets two dose ceilings and one internal narrowing band:
- 1–700 mg (claims 1 and 2)
- 5–100 mg (claim 3, and therefore method claims 6 and 9 via claim 3)
Claim “cliffs”
- 1 mg floor: below 1 mg/day (or below the defined daily amount if “daily dose” is construed that way) is outside the literal composition band.
- 700 mg ceiling: single-dose or daily dose above 700 mg sits outside claims 1–2.
- 5–100 mg band: if a product dose is designed to be outside 5–100 mg, it may avoid claim 3-based method claims (but not necessarily claims 4–5, which still sit in 1–700 mg).
Route limitation
All composition claims require oral administration. Products that are not oral (parenteral, transdermal, intranasal) are outside these claims.
Use limitation
Method claims require the clinical use: “anemia associated with renal disease in a human.”
That typically narrows the infringement theory for downstream manufacturers: they must sell/label/market a regimen intended for that indication, or be shown to administer that way in practice.
Where are the strongest and weakest infringement levers?
Strong levers for enforcement
- Dose overlap: any regimen with an oral daily dose of the compound (or salt) within 1–700 mg fits the independent composition framework.
- Indication match: anemia associated with renal disease is a specific therapeutic framing; a product labeled for that indication materially increases infringement risk on method claims.
- Daily dosing: claims 7–9 require “daily dose.” If an accused regimen uses non-daily dosing (for example, every other day), that could defeat those dependent claims, while leaving independent claims 4–6 (without the daily requirement) potentially at issue.
Potentially weak levers
- Generic excipient language: claims only require “pharmaceutically acceptable carriers, diluents or excipients.” Many oral formulations will satisfy that language, so excipient composition is unlikely to be a meaningful design-around unless the formulation can be argued not to be a “pharmaceutical composition” that meets the claim’s required components.
- No dosage form specification: design-around by switching between tablets and capsules is unlikely to help if dose and oral route are still met.
What is the legal “scope” of salts coverage?
Claim 1 includes “the compound: or a salt thereof.” That means a salt-formulation of the same compound could fall within claim 1 and, by extension, method claims relying on claim 1. Claim 2 lacks the salt language, so claim 2 targets the compound itself, while claim 1 extends to salts.
Business implication:
- If a competitor uses a salt form, claim 1-based composition coverage remains a risk.
- If a competitor uses a non-salt form, claim 1 can still be met if the “salt” limitation is not required. The salt language in claim 1 reads as inclusive (compound or salt), not exclusive.
What is missing from the claims that would otherwise narrow scope?
Based on the claim text provided, the patent does not limit scope by:
- therapeutic response thresholds (Hb improvement, transfusion reduction),
- renal disease stage or etiology,
- patient characteristics (age, baseline anemia severity),
- specific PK/PD claims,
- chemical identity.
As a result, the claim scope is dominated by:
- oral route,
- dose range,
- inclusion of excipients (generic),
- indication (for methods),
- daily dosing (for dependent method claims).
How should you map these claims to a patent landscape in the US?
Landscape map approach (claim-driven)
Because the claim text you provided does not include the compound’s chemical name, drug target, or reference patent family, the landscape must be mapped through claim features rather than compound identity. The highest-value landscape nodes are:
- Family-level US filings tied to the same compound and dosing concept.
- Formulation/dose patents for oral anemia treatment in renal disease.
- Use/indication patents targeting “anemia associated with renal disease” for oral regimens.
- Salt-form patents if the compound has known salt forms.
- Method-of-use claims with daily administration variants.
Most relevant infringement risk clusters
- Oral dosing in CKD anemia / renal disease anemia contexts: any oral product in that indication that doses within 1–700 mg daily could sit within claims 1/2 for compositions and claims 4/5 for methods.
- Mid-dose strategies (5–100 mg): products designed in that band face the tighter claim 3 coverage and method claim 6 (and 9 if daily).
Design-around zones implied by claims
Without compound identity, only generic design options can be inferred from the claim architecture:
- Reduce dose below 1 mg or exceed 700 mg (risks practicality and approvals).
- Avoid daily administration to attempt to defeat claims 7–9 (but not claims 4–6).
- Avoid oral route (unlikely if the product is oral by development plan).
- Avoid labeling or medical practice that is directed to “anemia associated with renal disease” (difficult to operationalize).
Are there likely continuation or divisional claim strategies here?
The claim set reads like a continuation of a core concept:
- composition with broad dose range (1–700 mg),
- narrowed subrange (5–100 mg),
- method of use aligned to the dose selection,
- daily dosing as dependent tightening.
This structure commonly appears in portfolios where applicants:
- maintain a broad independent composition anchor,
- add dependent claims to cover a range of clinically used doses,
- add schedule language to cover real-world dosing regimens.
What is the economic impact of the claim dose range?
The span 1–700 mg is unusually wide for a single active dose claim. If the compound is an oral small molecule where clinical regimens naturally fall into broad dosing windows, this width increases the probability of overlap with:
- multiple strength products,
- multiple label dose regimens,
- titration regimens.
The narrower 5–100 mg band still covers a large fraction of typical middle-dose oncology/hematology small-molecule dosing paradigms, increasing overlap with common dose selections.
Claim-by-claim scope grid
| Claim |
Coverage type |
Core limitations |
Key infringement axis |
| 1 |
Composition |
Oral; 1–700 mg; compound or salt; pharmaceutically acceptable excipients |
Dose within band; oral; compound/salt match |
| 2 |
Composition |
Oral; 1–700 mg; compound (no explicit salt phrasing); excipients |
Dose within band; oral; compound match |
| 3 |
Composition (dependent) |
Claim 2 base; 5–100 mg |
Dose within 5–100 mg |
| 4 |
Method (dependent on claim 1) |
Treat anemia associated with renal disease in human; administer claim 1 composition |
Indication + administration |
| 5 |
Method (dependent on claim 2) |
Same indication; administer claim 2 composition |
Indication + dose within 1–700 mg |
| 6 |
Method (dependent on claim 3) |
Same indication; administer claim 3 composition |
Indication + dose within 5–100 mg |
| 7 |
Method (dependent) |
Claim 4 + daily dose |
Dosing schedule |
| 8 |
Method (dependent) |
Claim 5 + daily dose |
Dosing schedule |
| 9 |
Method (dependent) |
Claim 6 + daily dose |
Dosing schedule and dose band |
Key Takeaways
- US 8,815,884 claims are centered on oral administration of a specified active “compound” (or salt) across a broad 1–700 mg dose range, plus excipients.
- The patent’s indication hook is anemia associated with renal disease in a human, making method claims more label/practice sensitive than pure formulation claims.
- Dependent narrowing to 5–100 mg creates a second layer of coverage that can be decisive if a competitor’s daily regimen sits in or near that band.
- Dependent claims 7–9 add daily dosing, so non-daily regimens may avoid those particular dependent method claims while leaving independent method claims potentially viable.
- The claims’ generic excipient language and lack of dosage form or release-profile limitations keep infringement risk high for most conventional oral formulation approaches that hit the same dose bands and indication.
FAQs
-
Does US 8,815,884 cover both the compound and its salts?
Yes. Claim 1 covers “the compound or a salt thereof.”
-
What dose range is independently claimed for oral compositions?
Claims 1 and 2 cover 1–700 mg.
-
What narrower dose band is specifically claimed?
Claim 3 narrows to 5–100 mg.
-
What is required for infringement of the method claims?
Administration to treat anemia associated with renal disease in a human using a composition that matches the relevant composition claim, with “daily dose” required for claims 7–9.
-
Can a different oral dosage form avoid infringement?
The claims do not specify a dosage form type, so changing tablets to capsules does not, by itself, avoid the claim unless it also changes dose, route, or the claimed daily dosing and indication alignment.
References
[1] US Patent 8,815,884.
More… ↓
⤷ Start Trial
|
